Actavis’ Bioequivalence Data Still Missing For Bupropion XL
This article was originally published in The Pink Sheet Daily
Executive Summary
Could the nearly five-month delay in submitting FDA mandated bioequivalence tests signal something is wrong with its two 300 mg bupropion generics?